{"id":"dicycloplatin-tp21","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Ototoxicity"},{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Peripheral neuropathy"}]},"_chembl":{"chemblId":"CHEMBL5411238","moleculeType":null,"molecularWeight":"2518.21"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a third-generation platinum compound, dicycloplatin binds to DNA and forms interstrand and intrastrand crosslinks, preventing DNA replication and transcription in cancer cells. This leads to cell cycle arrest and apoptosis. The drug is designed to have improved efficacy and potentially reduced nephrotoxicity compared to earlier platinum agents like cisplatin.","oneSentence":"Dicycloplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to inhibit cancer cell proliferation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:45:48.611Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT05472896","phase":"PHASE3","title":"TACE With Dicycloplatin(TP21) in Unresectable HCC","status":"UNKNOWN","sponsor":"Gao-jun Teng","startDate":"2022-06-09","conditions":"Hepatocellular Carcinoma","enrollment":332}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Dicycloplatin (TP21)","genericName":"Dicycloplatin (TP21)","companyName":"Gao-jun Teng","companyId":"gao-jun-teng","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dicycloplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to inhibit cancer cell proliferation. Used for Advanced or metastatic solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}